145 related articles for article (PubMed ID: 37559682)
1. Overexpression of ZEB1 and YAP1 is related to poor prognosis in patients with gliomas with different IDH1 status.
Miao N; Wang ZQ; Zhang N; Ma ZP; Su LP; Zhai YY; Hu YR; Sang W; Zhang W
Int J Clin Exp Pathol; 2023; 16(7):138-149. PubMed ID: 37559682
[TBL] [Abstract][Full Text] [Related]
2. Expression of YAP1 and pSTAT3-S727 and their prognostic value in glioma.
Sang W; Xue J; Su LP; Gulinar A; Wang Q; Zhai YY; Hu YR; Gao HX; Li X; Li QX; Zhang W
J Clin Pathol; 2021 Aug; 74(8):513-521. PubMed ID: 33020176
[TBL] [Abstract][Full Text] [Related]
3. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the expression and prognostic value of MT1-MMP, β1-integrin and YAP1 in glioma.
Zhai Y; Sang W; Su L; Shen Y; Hu Y; Zhang W
Open Med (Wars); 2022; 17(1):492-507. PubMed ID: 35350840
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
6. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
8. The Expression and Prognostic Value of ILK and YAP1 in Glioma.
Wang Q; Sang W; Xue J; Zhai Y; Hu Y; Su L; Zhang W
Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):e21-e29. PubMed ID: 35262527
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
11. YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas.
Patrick S; Gowda P; Lathoria K; Suri V; Sen E
J Cell Sci; 2021 Nov; 134(22):. PubMed ID: 34651186
[TBL] [Abstract][Full Text] [Related]
12. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
13. Proteomics reveals protein phosphatase 1γ as a biomarker associated with Hippo signal pathway in glioma.
Xue J; Sang W; Su LP; Gao HX; Cui WL; Abulajiang G; Wang Q; Zhang J; Zhang W
Pathol Res Pract; 2020 Nov; 216(11):153187. PubMed ID: 32919304
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of
Huang SP; Chan YC; Huang SY; Lin YF
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861486
[TBL] [Abstract][Full Text] [Related]
15. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
16. Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Patrick S; Lathoria K; Suri V; Sen E
Cell Signal; 2023 Sep; 109():110738. PubMed ID: 37269960
[TBL] [Abstract][Full Text] [Related]
17. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
Deng X; Lin D; Chen B; Zhang X; Xu X; Yang Z; Shen X; Yang L; Lu X; Sheng H; Yin B; Zhang N; Lin J
Front Oncol; 2019; 9():1310. PubMed ID: 31824866
[TBL] [Abstract][Full Text] [Related]
19. Twist predicts poor outcome of patients with astrocytic glioma.
Nordfors K; Haapasalo J; Mäkelä K; Granberg KJ; Nykter M; Korja M; Paavonen T; Haapasalo H; Soini Y
J Clin Pathol; 2015 Nov; 68(11):905-12. PubMed ID: 26163539
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Zinc Finger E-Box-Binding Homeobox Family in Glioblastoma.
Chen P; Liu H; Hou A; Sun X; Li B; Niu J; Hu L
Med Sci Monit; 2018 Feb; 24():1145-1151. PubMed ID: 29476046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
